- Home
- ANVS vs PMVP Comparison
ANVS vs PMVP Comparison
Compare ANVS & PMVP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ANVS | PMVP |
|---|---|---|
| Founded | 2008 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 111.3M | 66.0M |
| IPO Year | 2020 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ANVS | PMVP |
|---|---|---|
| Price | $3.99 | $1.26 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $13.50 | $5.00 |
| AVG Volume (30 Days) | ★ 1.3M | 291.0K |
| Earning Date | 11-12-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.11 | $0.81 |
| 52 Week High | $5.60 | $1.84 |
Technical Indicators
Market Signals| Indicator | ANVS | PMVP |
|---|---|---|
| Relative Strength Index (RSI) | 53.31 | 47.83 |
| Support Level | $3.46 | $1.11 |
| Resistance Level | $4.05 | $1.28 |
| Average True Range (ATR) | 0.38 | 0.07 |
| MACD | -0.14 | 0.01 |
| Stochastic Oscillator | 35.29 | 70.00 |
Price Performance
Historical ComparisonAbout ANVS Annovis Bio Inc.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.
About PMVP PMV Pharmaceuticals Inc.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. Its pipeline rezatapopt PYNNACLE, rezatapopt and azacitidine, rezatapopt (PC14586), and PMV-586-101.